Pharmaceuticals, Biotechnology and Life Sciences
The launch marks MediCane’s entry into the pharmaceutical sector of a major European market. For Dr. Reddy’s, the launch reinforces its presence in Germany’s growing medical cannabis market
Vivoryon Therapeutics N.V. has completed a private placement by way of accelerated bookbuilding, placing 2,000,000 registered shares at an offering price of EUR 10.50 per share.
Sanofi has announced that the French Autorité des marchés financiers (AMF) has approved the listing prospectus prepared by EUROAPI in connection with the intended listing of its shares on the regulated market of Euronext Paris.
LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022.
Achieving classical herd immunity against SARS-CoV-2, the virus that causes COVID-19, may not be attainable, according to a new perspective published in The Journal of Infectious Diseases.
Vivoryon Therapeutics N.V., a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, has announced the launch of a private placement by way of an accelerated bookbuilding process to institutional investors offering up to 2,000,000 newly issued registered shares, representing up to approximately 10% of the company’s issued share capital.
Abzena Thrusday announced a new round of investment. Funding sources for the additional $65 million include majority-owner Welsh, Carson, Anderson & Stowe (WCAS), Biospring Partners, and other affiliated investors.
The Solvay Brussels School of Economics and Management in collaboration with the ULB research institute I3h has launched a new Advanced Master in Biotech & MedTech Ventures. The programme addresses the thriving Belgian and European life sciences’ need for young entrepreneurial talent capable of taking on (C-level) management positions in early-stage Biotech and MedTech companies.
V-Bio Ventures has announced the final closing of its second fund, V-Bio Fund 2, having raised EUR 110 million euro and exceeding its target of EUR 100 million.
Symbiosis Pharmaceutical Services Ltd, a contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has completed a £1.3 million collaborative UKRI-funded project as part of the medicines manufacturing challenge.